Glenmark Pharmaceuticals Inc., USA has launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. This product is bioequivalent and therapeutically equivalent to the reference listed drug. According to IQVIA data, the Epinephrine Injection market achieved annual sales of approximately $67.6 million. This launch expands Glenmark’s portfolio within the institutional channel, offering affordable alternatives for patients.
Epinephrine Injection USP Launch
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced on December 23, 2025, the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. This launch marks an expansion of Glenmark’s product offerings in the United States.
Product Equivalence
Glenmark’s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029. This ensures patients receive the same therapeutic benefits.
Market Opportunity
According to IQVIA™ sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market achieved annual sales of approximately $67.6 million*. Glenmark’s entry into this market presents a significant opportunity for growth.
Comments on the Launch
Marc Kikuchi, President & Business Head, North America, stated, “We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”
Source: BSE